Iright
BRAND / VENDOR: Abcam

Abcam, ab284817, Anti-Factor VII antibody [EP6185(2)] - BSA and Azide free

CATALOG NUMBER: ab284817
Precio habitual$0.99
/
Los gastos de envío se calculan en la pantalla de pagos.
  • ddddd

    99 xxxxxx

  • Pedido pendiente, envío pronto

Este sitio está protegido por hCaptcha y se aplican la Política de privacidad de hCaptcha y los Términos del servicio.

Product Description

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Factor VII antibody. Carrier free. Suitable for WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP6185(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab284817 is the carrier-free version of
ab151543
This product has switched from a hybridoma to recombinant production method on 9th June 2023.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Factor VII also known as factor 7 or factor seven is a plasma glycoprotein with a molecular mass of approximately 50 kDa. It plays an important role in the blood coagulation process. Factor VII is mainly produced in the liver and requires vitamin K for its synthesis. In the inactive form it circulates in the plasma but upon activation to factor 7a it initiates the extrinsic pathway of blood coagulation. This activation is a critical step in hemostasis which helps to prevent excessive bleeding.
Biological function summary
Factor 7a indirectly activates further components in the blood coagulation cascade. Upon activation factor 7a becomes a part of the tissue factor (TF) complex which includes tissue factor expressed on subendothelial cells. The complex triggers the activation of factor IX and factor X propagating the coagulation cascade downstream. This series of activations amplifies the signal for clot formation highlighting factor VII's integral role in initiating coagulation.
Pathways
Factor VII is primarily involved in the extrinsic pathway of the coagulation cascade. This pathway is initiated when factor 7a forms a complex with tissue factor a protein that becomes exposed at injury sites. Factor VII is also indirectly linked to the common coagulation pathway through activation of factor X. The interaction between these pathways ensures efficient and rapid clot formation. Additionally factor IX also interacts with factor VII in the intricate network of coagulation processes that sustain hemostasis.
Deficiencies or dysfunctions in factor VII can lead to coagulopathies such as congenital factor VII deficiency which results in excessively prolonged bleeding. Conversely elevated factor VII activity can contribute to thromboembolic disorders like myocardial infarction. In these conditions factor VII often interacts with proteins like factor X and tissue factor highlighting their clinical significance in managing blood coagulation abnormalities.


Order Guidelines

1. Price & Stock Available on Request. 📧Click to send email to: service@iright.com

2. Please DO NOT make payment before confirmation.

3. Minimum order value of $1,000 USD required.

Collaboration

Tony Tang

📧Email: Tony.Tang@iright.com

📱Mobile/WhatsApp/Wechat: +86-17717886924